Bionano Genomics (BNGO) Equity Average (2018 - 2026)

Bionano Genomics' Equity Average history runs 9 years deep, the most recent figure standing at $40.9 million for Q1 2026.

• In Q1 2026, Equity Average fell 2.01% year-over-year to $40.9 million; the TTM figure through Mar 2026 stood at $40.9 million (down 2.01% YoY), while the FY2025 annual figure was $39.9 million, down 39.33% from the prior year.
• Equity Average came in at $40.9 million for Q1 2026 at Bionano Genomics, down from $47.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $324.2 million in Q1 2022 to a low of $40.9 million in Q1 2026.
• A 5-year average of $141.8 million and a median of $89.5 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average surged 62.97% in 2022 and sank 63.45% in 2024, its largest moves.
• Bionano Genomics' Equity Average stood at $265.6 million in 2022, then plunged by 59.49% to $107.6 million in 2023, then tumbled by 60.85% to $42.1 million in 2024, then rose by 11.85% to $47.1 million in 2025, then fell by 13.09% to $40.9 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $40.9 million, $47.1 million, and $47.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison